Connect Biopharma Holdings (CNTB) Income from Continuing Operations (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted quarterly Income from Continuing Operations of 19398000.0 for Q1 2026, down 88.84% year-on-year from 173871078.53 in Q1 2025, and down 28.39% on a QoQ basis from 15109000.0 in Q4 2025.
Connect Biopharma Holdings (CNTB) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Income from Continuing Operations for 3 consecutive years, with 19398000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 88.84% year-over-year to 19398000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 64606000.0 (down 275.46% YoY) and the FY2025 annual result came in at 55480000.0, down 255.0% from the prior year.
- Income from Continuing Operations eased to 19398000.0 in Q1 2026 per CNTB's latest filing, from 15109000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for CNTB reached as high as 14847000.0 in Q2 2024 and fell as low as 19398000.0 in Q1 2026.
- A 3-year average of 10056222.22 and a median of 12876000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The largest YoY upside for Income from Continuing Operations was 18.16% in 2025 against a maximum downside of 186.88% in 2025.
- Year by year, Income from Continuing Operations stood at 8906000.0 in 2024, then plunged by 69.65% to 15109000.0 in 2025, then dropped by 28.39% to 19398000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 19398000.0, 15109000.0, and 17200000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Connect Biopharma Holdings | 120.44 Mn | 120.44 Mn | - | -19.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.40 Mn |
| Dec 31, 2025 | -15.11 Mn |
| Sep 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -12.90 Mn |
| Mar 31, 2025 | -10.27 Mn |
| Dec 31, 2024 | -8.91 Mn |
| Sep 30, 2024 | -12.88 Mn |
| Jun 30, 2024 | 14.85 Mn |
| Mar 31, 2024 | -8.69 Mn |